$3.23
+0.09(2.93%)
Mkt Cap $172M
$1.98
$5.83
52-Week Range
At a Glance
AI-generatedAchieve Life Sciences, Inc.
8-K
Achieve Life Sciences announced Q4 and full year 2025 financial results, reporting net losses of $14.7 million and $54.7 million, respectively, with $36.4 million in cash as of December 31, 2025. Updates include FDA acceptance of cytisinicline NDA with PDUFA date of June 20, 2026, completion of ORCA-OL trial, and partnership with Adare Pharma Solutions for U.S. manufacturing ahead of potential 2027 launch.$172M
Market Cap
—
Revenue
-$80M
Net Income
Employees25
Fundamentals
How The Business Makes Money
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Industry Biotechnology
Activity
Company Profile
CIK0000949858
ISINUS0044685008
CUSIP004468203
Phone14256861500
Address1040 West Georgia Street, Vancouver, BC, V6E 4H1, CA
SEC EDGAR